Covered recipient · General Payments record
SREELEKHA SUSARLA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$1,389.77
- Reported across 76 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $354.93 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $80.54 | 4 |
| GlaxoSmithKline, LLC. | $58.22 | 3 |
| ABBVIE INC. | $42.81 | 2 |
| Novo Nordisk AS | $39.94 | 2 |
| Merck Sharp & Dohme Corporation | $36.13 | 2 |
| Acerta Pharma LLC | $33.63 | 2 |
| ABIOMED | $28.92 | 1 |
| Xeris Pharmaceuticals, Inc. | $20.97 | 1 |
| DAVOL INC. | $13.77 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.51 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106185727 | CMS |
| ABBVIE INC. | $25.30 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106185729 | CMS |
| ABIOMED | $28.92 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142269739 | CMS |
| Amgen Inc. | $26.50 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117695815 | CMS |
| Amgen Inc. | $19.47 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116163194 | CMS |
| Amgen Inc. | $19.68 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116163208 | CMS |
| Amgen Inc. | $14.89 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116163202 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.06 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105500894 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.57 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104785244 | CMS |
| Davol Inc. | $13.77 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127643789 | CMS |
| GlaxoSmithKline, LLC. | $20.16 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116231131 | CMS |
| GlaxoSmithKline, LLC. | $20.71 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116583991 | CMS |
| GlaxoSmithKline, LLC. | $17.35 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116692829 | CMS |
| Merck Sharp & Dohme LLC | $13.99 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141752710 | CMS |
| Merck Sharp & Dohme LLC | $22.14 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141887005 | CMS |
| Novo Nordisk Inc | $23.53 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097695899 | CMS |
| Novo Nordisk Inc | $16.41 | 08/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097600441 | CMS |
| Xeris Pharmaceuticals, Inc. | $20.97 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144614116 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.